• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Vor Biopharma Inc.

    7/1/25 4:58:17 PM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $VOR alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001741283
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    VOR BIOPHARMA, INC.
    SEC File Number
    001-39979
    Address of Issuer
    100 Cambridgepark Drive, Suite 101
    Cambridge
    MASSACHUSETTS
    02140
    Phone
    (617) 655-6580
    Name of Person for Whose Account the Securities are To Be Sold
    ROBERT ANG
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer
    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Morgan Stanley Smith Barney LLC Executive Financial Services
    1 New York Plaza
    8th Floor
    New York � NY � 10004
    4046869613.0512495952007/01/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common03/01/2023Restricted StockIssuerCheckbox not checked2446803/01/2023Not Applicable
    Common09/01/2023Restricted StockIssuerCheckbox not checked1600009/01/2023Not Applicable

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    ROBERT ANG
    100 Cambridgepark Drive, Suite 101
    Cambridge � MA � 02140
    Common06/30/202556869837.35
    ROBERT ANG
    100 Cambridgepark Drive, Suite 101
    Cambridge � MA � 02140
    Common06/30/202556869837.35
    ROBERT ANG
    100 Cambridgepark Drive, Suite 101
    Cambridge � MA � 02140
    Common06/30/202556869837.35
    ROBERT ANG
    100 Cambridgepark Drive, Suite 101
    Cambridge � MA � 02140
    Common06/30/202552599098.60
    ROBERT ANG
    100 Cambridgepark Drive, Suite 101
    Cambridge � MA � 02140
    Common06/30/2025662411460.18
    ROBERT ANG
    100 Cambridgepark Drive, Suite 101
    Cambridge � MA � 02140
    Common06/30/202556869837.35
    ROBERT ANG
    100 Cambridgepark Drive, Suite 101
    Cambridge � MA � 02140
    Common06/30/2025600010380.60

    144: Remarks and Signature

    Remarks
    Date of Notice
    07/01/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Robert Ang

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $VOR alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $VOR

    DatePrice TargetRatingAnalyst
    6/30/2025$3.00Neutral → Buy
    H.C. Wainwright
    7/26/2022$18.00Outperform
    Wedbush
    4/27/2022$6.00Neutral
    Goldman
    12/17/2021$26.00Buy
    HC Wainwright & Co.
    12/3/2021$38.00Outperform
    Robert W. Baird
    12/3/2021$38.00Outperform
    Baird
    12/2/2021$30.00Outperform
    Oppenheimer
    10/19/2021$40.00Market Outperform
    JMP Securities
    More analyst ratings

    $VOR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Reprogrammed Interchange Llc bought 38,974,101 shares (SEC Form 4)

      4 - Vor Biopharma Inc. (0001817229) (Issuer)

      1/2/25 7:42:04 PM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VOR
    SEC Filings

    See more
    • SEC Form 144 filed by Vor Biopharma Inc.

      144 - Vor Biopharma Inc. (0001817229) (Subject)

      7/2/25 4:40:26 PM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 144 filed by Vor Biopharma Inc.

      144 - Vor Biopharma Inc. (0001817229) (Subject)

      7/1/25 4:58:17 PM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 144 filed by Vor Biopharma Inc.

      144 - Vor Biopharma Inc. (0001817229) (Subject)

      6/30/25 5:15:16 PM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VOR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by CEO and Chairman Kress Jean-Paul

      4 - Vor Biopharma Inc. (0001817229) (Issuer)

      6/27/25 4:10:08 PM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Kress Jean-Paul

      3 - Vor Biopharma Inc. (0001817229) (Issuer)

      6/27/25 4:09:13 PM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Ra Capital Management, L.P.

      4 - Vor Biopharma Inc. (0001817229) (Issuer)

      5/23/25 5:47:06 PM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VOR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Vor Biopharma upgraded by H.C. Wainwright with a new price target

      H.C. Wainwright upgraded Vor Biopharma from Neutral to Buy and set a new price target of $3.00

      6/30/25 7:56:45 AM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Wedbush initiated coverage on Vor Biopharma with a new price target

      Wedbush initiated coverage of Vor Biopharma with a rating of Outperform and set a new price target of $18.00

      7/26/22 8:25:46 AM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Goldman initiated coverage on Vor Biopharma with a new price target

      Goldman initiated coverage of Vor Biopharma with a rating of Neutral and set a new price target of $6.00

      4/27/22 6:14:19 AM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VOR
    Leadership Updates

    Live Leadership Updates

    See more
    • Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors

      CAMBRIDGE, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Mr. Erez Kalir to its Board of Directors. The appointment represents a new seat on Vor Bio's Board of Directors, which has been created in connection with the recent private investment in public equity financing (PIPE) which was led by Reid Hoffman. Mr. Kalir will serve as the director designee of Reprogrammed Interchange, LLC, Mr. Hoffman's investment fund. Mr. Kalir brings a wealth of experience as an investor, entrepreneur, and thought leader with a deep focus on life sciences and technology. Currently the Managing Member of

      1/8/25 9:00:00 AM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer

      CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Han Choi, M.D., LL.M., as its new Chief Financial Officer, effective immediately. Dr. Choi will join the Vor Bio leadership team and will report directly to the company's President and Chief Executive Officer, Dr. Robert Ang. Dr. Choi brings to Vor Bio over twenty-five years of experience in public and private investment management, business development, and corporate strategy within the pharmaceutical and biotechnology industry. His deep expertise in structuring corporate partnerships and investments, managing complex transact

      9/30/24 7:00:00 AM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors

      CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Fouad Namouni, M.D., to its Board of Directors. Dr. Namouni currently serves as President of Research & Development at Blueprint Medicines, bringing a wealth of industry experience and expertise to Vor Bio's Board. In his role at Blueprint Medicines, Dr. Namouni has demonstrated exceptional leadership in building the company's fully integrated business and advancing a broad pipeline of innovative medicines to address significant medical needs in oncology/hematology and allergy/inflammation. With over two decades of experience in

      5/2/24 4:01:00 PM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VOR
    Financials

    Live finance-specific insights

    See more
    • Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

      CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced that, based on currently available clinical data from its key clinical programs and a challenging fundraising environment, the Board of Directors has approved the initiation of a process to explore a range of strategic alternatives aimed at maximizing both near- and long-term shareholder value.   These strategic alternatives could include, among other alternatives, a potential sale of assets of the Company, a potential licensing of assets of the Company, a sale of the Company, a business combination, a merger or other strategic action. The Company

      5/8/25 8:30:15 AM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design

      Preliminary data suggests improved relapse-free survival compared to published groups of acute myeloid leukemia (AML) patients at high risk of relapse post-transplantTrem-cel + Mylotarg continue to demonstrate engraftment, shielding, and broadened therapeutic windowCompany has received supportive feedback from the FDA regarding a registrational clinical trial design CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced updated clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory AML receiving trem-cel followed by Mylotarg™. The data, which was presented in a post

      12/9/24 7:30:00 AM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • New Clinical Data Validates Vor Bio's Approach of Using Shielded Transplants to Deliver Targeted Therapies

      Trem-cel + Mylotarg demonstrated engraftment, shielding, broadened therapeutic window, and patient benefitVCAR33ALLO demonstrates encouraging biomarker data at lowest dose New asset VADC45 with significant potential opportunities across oncology, gene therapy, and autoimmune disorders CAMBRIDGE, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced new clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory AML receiving trem-cel followed by Mylotarg™. The data demonstrated reliable engraftment, shielding from Mylotarg on-target toxicity, a broadened Mylotarg therapeutic wind

      9/5/24 4:01:00 PM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VOR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      CAMBRIDGE, Mass., July 01, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, effective as of June 26, 2025, the Board of Directors granted Jean-Paul Kress, the Company's Chief Executive Officer, an option to purchase 83,296,638 shares of Vor Bio's common stock in connection with the commencement of his employment. The foregoing stock option was granted as a material inducement to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and was granted under the Vor Biopharma Inc. 2023 Inducement Plan (the "Inducement Plan"). The stock option has a ten-year term and

      7/1/25 4:00:00 PM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • PureTech Founded Entity Vor Bio Announces Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset and $175 Million Private Placement

      PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, noted that its Founded Entity, Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, and RemeGen Co., Ltd. (HKEX: 9995, SHA: 688331) announced entry into an exclusive license agreement granting Vor Bio global rights (excluding China, Hong Kong, Macau and Taiwan) to develop and commercialize telitacicept, a novel dual-target fusion protein approved in China for generalized myasthenia gravis (gMG), systemic lupus erythematosus (SLE), and rheumatoid a

      6/26/25 2:00:00 AM ET
      $PRTC
      $VOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Vor Bio Announces $175 Million Private Placement

      CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it has entered into a securities purchase agreement for a private placement in public equity financing (the "PIPE") that is expected to result in gross proceeds of approximately $175 million, before deducting expenses. Private Placement Pursuant to the terms of the securities purchase agreement, at the closing of the PIPE, Vor Bio will issue prefunded warrants (the "Warrants") to purchase an aggregate of 700,000,000 shares of common stock at a purchase price of $0.25 per Warrant. The PIPE included a syndi

      6/25/25 4:50:16 PM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VOR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Vor Biopharma Inc.

      SC 13G/A - Vor Biopharma Inc. (0001817229) (Subject)

      11/14/24 4:33:50 PM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Vor Biopharma Inc. (Amendment)

      SC 13D/A - Vor Biopharma Inc. (0001817229) (Subject)

      2/14/24 4:17:24 PM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Vor Biopharma Inc. (Amendment)

      SC 13G/A - Vor Biopharma Inc. (0001817229) (Subject)

      2/14/24 4:08:06 PM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care